3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
23
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
485
Lymphoma, T-Cell, Cutaneous
92
Carcinoma, Non-Small-Cell Lung
89
Mycosis Fungoides
72
Neoplasm Metastasis
71
Skin Neoplasms
62
Neoplasms
61
Sezary Syndrome
60
Carcinoma, Renal Cell
60
Lymphoma, Non-Hodgkin
53
Lymphoma, Large B-Cell, Diffuse
53
Lymphoma
53
Breast Neoplasms
51
Leukemia, Lymphocytic, Chronic, B-Cell
50
Lymphoma, Follicular
47
Lymphoma, Mantle-Cell
46
Lymphoma, B-Cell, Marginal Zone
46
Squamous Cell Carcinoma of Head and Neck
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Hodgkin Disease
44
Colorectal Neoplasms
43
Burkitt Lymphoma
43
Lymphoma, Large-Cell, Immunoblastic
41
Ovarian Neoplasms
38
Multiple Myeloma
35
Uveal Melanoma
34
Leukemia, Hairy Cell
33
Lymphoma, Large-Cell, Anaplastic
32
Sarcoma
31
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
31
Interventions
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Non-Muscle Invasive Bladder Neoplasms
×
Dermatologic
×
Clear all
NCT06448364
2024-11-06
LTbR
Pfizer
Phase 1
Terminated
4 enrolled